Alchemab Therapeutics

Alchemab Therapeutics, founded in 2019 and based in Cambridge, UK, has developed a unique platform that reverse-engineers protective immunity from resilient patient populations to discover novel antibody therapeutics. The company's approach identifies common antibody signatures among individuals who naturally resist or overcome severe diseases, enabling the development of therapeutics with a potentially high probability of success. With a lead program, ATLX-1282, now in Phase 1 and a focus on neurodegeneration and oncology, Alchemab is positioning itself at the intersection of computational biology and antibody drug discovery. The company is privately held, backed by venture capital, and is actively expanding its business development efforts.

Proprietary platform that identifies convergent protective antibody responses from deep B cell sequencing of resilient patient cohorts (e.g., long-term cancer survivors) using computational analysis.

Competes with numerous biotechs in antibody discovery (e.g., AbCellera, Distributed Bio) and neurodegeneration (e.g., Biogen, Denali). Its unique differentiator is the focus on convergent antibodies from pre-identified resilient patients, a niche approach versus high-throughput screening or target-based methods.